MassMutual Private Wealth & Trust FSB Decreases Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

MassMutual Private Wealth & Trust FSB decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 41.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,087 shares of the medical research company’s stock after selling 755 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Charles River Laboratories International were worth $201,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in CRL. Wolff Wiese Magana LLC purchased a new position in shares of Charles River Laboratories International in the 3rd quarter worth approximately $32,000. Versant Capital Management Inc grew its holdings in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares during the last quarter. Assetmark Inc. increased its position in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares during the period. Pinnacle Bancorp Inc. boosted its holdings in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new position in Charles River Laboratories International in the third quarter worth approximately $59,000. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Trading Down 0.9 %

Shares of NYSE:CRL opened at $168.27 on Thursday. The business’s 50-day moving average is $187.81 and its 200 day moving average is $197.72. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 1 year low of $160.85 and a 1 year high of $275.00. The firm has a market capitalization of $8.61 billion, a P/E ratio of 21.06, a P/E/G ratio of 5.75 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm posted $2.72 EPS. On average, research analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on CRL shares. TD Cowen upped their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Evercore ISI raised their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and a consensus price target of $209.00.

Insiders Place Their Bets

In related news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).